BPTH (Bio-Path Holdings, Inc) Forward P/E Multiple

Bio-Path Holdings (BPTH) combines a closed RNA therapy ecosystem with the scalable production of DNA drugs. The company's forward P/E ratio on the GURU.Markets chart reconciles these approaches, while the 0.00 level captures fresh values. Currently in the pre-revenue stage, Bio-Path Holdings is competing for priority in clinical trials using its proprietary targeted therapy methods.

Future Price to Earnings: Bio-Path Holdings, Inc. (BPTH) for 07/04/2022 - 03/01/2025

Summary analytical data breakdowns for Bio-Path Holdings, Inc (BPTH)

- current price and projected stock value:

Stock Quotes Bio-Path Holdings, Inc.|BPTH - Fair Value Consensus

- business market valuation indicators:

Market Capitalization Bio-Path Holdings Inc.|BPTH - Total Company Value

- book capitalization information:

Net Assets per Single Share Bio-Path Holdings|BPTH - Company Book Value|Market Value to Book Value Ratio biopathholdings.com|BPTH - Company Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

BPTH - Company Net Income|Future Profit Bio-Path Holdings|BPTH - Market Cap to Net Income Ratio|Future Price to Earnings Bio-Path|BPTH - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Bio-Path Holdings Inc.|BPTH - Operating profit EBITDA|Net earnings per share for the last 12 months Bio-Path Holdings|BPTH - Earnings per share for the last four quarters|Quarterly EPS earnings growth biopathholdings.com|BPTH - Earnings per share increase in current year|Expected earnings per share growth for next year Bio-Path Holdings

Summary company analytics:Bio-Path Holdings, Inc.

Signature product of Bio-Path Holdings, Inc

Bio-Path Holdings (BPTH) reliance on external CROs and CMOs for oncology drug development makes future profits sensitive to the operational risks of contractors. By analyzing the company's forward P/E, an investor compares the current share price with expected earnings to determine the extent of the embedded premium for business scalability; deviations on this chart signal an overvaluation or undervaluation of the issuer's expansion potential.

Competing companies